Sapience Therapeutics signs license deal with Columbia University for novel cancer treatment
Under the terms of the agreement, Sapience will gain exclusive rights to the development and commercialization of intellectual property developed at Columbia University by Drs. Lloyd Greene and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.